Policy & Regulation
Twist Bioscience to Provide Antibody Discovery, Optimization and Access to Library of Libraries for Drug Research to Stanford University Laboratories
7 April 2021 - - US-based synthetic DNA company Twist Bioscience Corp. (NASDAQ: TWST) has signed an agreement enabling multiple academic laboratories at Stanford University to access Twist Bioscience's antibody discovery and optimization services as well as its unique "Library of Libraries" for biologics discovery, the company said.

Each academic laboratory working through the IMA may independently access the "Library of Libraries" and once accessed, has the option to use this robust discovery tool to discover new biologics against their specified target, or to have Twist Biopharma conduct the discovery and optimization work.

Twist will receive technology access fees for each lab that accesses the "Library of Libraries" and will share in revenue of all antibodies that are outlicensed for further development.

The first project under the agreement focuses on discovery of novel antibodies to a neuroscience target from the lab of Katrin Andreasson, M.D., professor of neurology at the Stanford University School of Medicine.

By leveraging Twist's unique ability to manufacture DNA at scale, researchers can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body.

This "Library of Libraries" gives Twist's partners an integral and unbiased resource for antibody therapeutic discovery and optimization.

This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.

Twist Bioscience is a synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.

Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, and antibody libraries for drug discovery and development.

Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.


Related Headlines